c
2
12
18
28
12
12
1a
14
e
12
16
a
a
2
2
a
20
32
1a
2a
19
Faculty
61 16
19
1
49
2
2
1a
32
34
1b
1d
18
33
49
1d
2 29
1d
25
Peter M.J. Quinn, PhD
88
49
Assistant Professor of Ophthalmology
7
64
Department: Ophthalmology
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
5b
4
3
3
3
2
4
b
1f
5b
F.M. Kirby Center for Molecular Ophthalmology
2d Stellar Chance Laboratories, Room 315
32 422 Curie Blvd.
Philadelphia, PA 19104
26
2d Stellar Chance Laboratories, Room 315
32 422 Curie Blvd.
Philadelphia, PA 19104
35
f
13
Education:
21 8 BSc 20 (Biological Sciences) c
31 University of Manchester, 2008.
21 8 MSc 33 (Molecular Medicine and Cancer Research) c
2a Brunel University, 2011.
21 8 PhD 28 (Department of Ophthalmology) c
39 Leiden University Medical Center, 2019.
c
3
27
5
3
3
92
Permanent link21 8 BSc 20 (Biological Sciences) c
31 University of Manchester, 2008.
21 8 MSc 33 (Molecular Medicine and Cancer Research) c
2a Brunel University, 2011.
21 8 PhD 28 (Department of Ophthalmology) c
39 Leiden University Medical Center, 2019.
c
2 29
21
1e
1d
24
76
8
14b Keywords: cell polarity, neurodegeneration, gene therapy, gene augmentation, CRISPR/CAS, gene editing, prime editing, induced pluripotent stem cells (iPSCs), organoids, inherited retinal diseases (IRDs), retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), autosomal dominant optic atrophy (ADOA), genetic glaucoma.
8
22a Research Details: The labs focus is to provide clinically translatable impact using iPSC-derived ophthalmic organoid-based approaches for the understanding and treatment of retinal degenerative diseases. The PrimeSight team are currently developing gene-specific and gene-agnostic therapeutics for the amelioration of the phenotypic, histopathological, and molecular changes in several inherited retinal disease iPSC-derived retinal organoid models. Further, they are establishing projects on autosomal dominant optic atrophy and genetic glaucoma.
e 29
27
Description of Research Expertise
63 Research Interests: Mechanisms and therapeutics for retinal degenerative diseases.8
14b Keywords: cell polarity, neurodegeneration, gene therapy, gene augmentation, CRISPR/CAS, gene editing, prime editing, induced pluripotent stem cells (iPSCs), organoids, inherited retinal diseases (IRDs), retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), autosomal dominant optic atrophy (ADOA), genetic glaucoma.
8
22a Research Details: The labs focus is to provide clinically translatable impact using iPSC-derived ophthalmic organoid-based approaches for the understanding and treatment of retinal degenerative diseases. The PrimeSight team are currently developing gene-specific and gene-agnostic therapeutics for the amelioration of the phenotypic, histopathological, and molecular changes in several inherited retinal disease iPSC-derived retinal organoid models. Further, they are establishing projects on autosomal dominant optic atrophy and genetic glaucoma.
e 29
23
1eb Quinn PM, Buck TM, Mulder AA, Ohonin C, Alves CH, Vos RM, Bialecka M, van Herwaarden T, van Dijk EHC, Talib M, Freund C, Mikkers HMM, Hoeben RC, Goumans MJ, Boon CJF, Koster AJ, Chuva de Sousa Lopes SM, Jost CR, Wijnholds J.: Human iPSC-Derived Retinas Recapitulate the Fetal CRB1 CRB2 Complex Formation and Demonstrate that Photoreceptors and Müller Glia Are Targets of AAV5. Stem Cell Reports 12: 906-919, May 2019.
19f Buck TM, Quinn PMJ, Pellissier LP, Mulder AA, Jongejan A, Koot D, Almushattat H, Arendzen CH, Vos RM, Bradley EJ, Freund C, Mikkers HMM, Boon CJF, van Kampen AH, Baas F, Koster AJ, Neefjes J, Berlin I, Jost CR, Wijnholds J. : CRB1 is required for recycling by RAB11A+ vesicles in human retinal organoids. Stem Cell Reports 18, September 2023.
133 Marques JP, Sousa IS, Patrício D, Simões BF, Chukwunalu O, Zeitz C, Audo I, Collin RWJ, Quinn PMJ, Ambrósio AF, Alves CH: Eyes shut homolog (EYS): Connecting molecule to disease. Progress in Retinal and Eye Research September 2025.
12c Stehle IF, Imventarza JA, Woerz F, Antony S, Hoffmann F, Boldt K, Beyer T, Quinn PMJ, Ueffing M. : Human CRB1-CRB2 interaction support CRB2 as a modifier in CRB1-associated retinal diseases. Life Science Alliance. April 2024.
172 Balasubramanian R, Min X, Quinn PMJ, Giudice QL, Tao C, Polanco K, Makrides N, Peregrin J, Bouaziz M, Mao Y, Wang Q, da Costa BL, Buenaventura D, Wang F, Ma L, Tsang SH, Fabre PJ, Zhang X.: Phase transition specified by a binary code patterns the vertebrate eye cup. Sci Adv 7: eabj9846, Nov 2021.
164 Costa BLD, Quinn PMJ, Wu WH, Nolan ND, Liu S, Wang NK, Demirkol A, Caruso SM, Tsai YT, Kong Y, Cabral T, Belfort R, Tsang SH. : Downregulation of miR-181a/b reprograms the retinal pigment epithelium metabolism in a mouse model of retinitis pigmentosa. Cell and Bioscience. May 2024.
106 Caruso SM, Tsai YT, da Costa BL, Kolesnikova M, Jenny LA, Tsang SH, Quinn PMJ.: Prime Editing Strategy to Install the PRPH2 c.828+1G>A Mutation. Adv Exp Med Biol 1415(1): 97-102, July 2023.
114 Tsai YT, da Costa BL, Caruso SM, Nolan ND, Levi SR, Tsang SH, Quinn PMJ.: Generation of an Avian Myeloblastosis Virus (AMV) Reverse Transcriptase Prime Editor. Adv Exp Med Biol 1415: 109-114, July 2023.
10d Lopes da Costa B, Kolesnikova M, Levi SR, Cabral T, Tsang SH, Maumenee IH, Quinn PMJ.: Clinical and Therapeutic Evaluation of the Ten Most Prevalent CRB1 Mutations. Biomedicines 11: 385, Jan 2023.
2c
7
1d
1f
Selected Publications
162 Costa BLD, Helms KM, Theodore K, Tsai Y-T, Caruso SM, Liu S, Carvalho JRL, Nolan ND, Tahir S, Makinson CD, Tsang SH, Quinn PMJ: Prime Editing for the Investigation of Aberrant Splicing Defect Associated with a Pathogenic PRPH2 Variant. Molecular Therapy Nucleic Acids October 2025.1eb Quinn PM, Buck TM, Mulder AA, Ohonin C, Alves CH, Vos RM, Bialecka M, van Herwaarden T, van Dijk EHC, Talib M, Freund C, Mikkers HMM, Hoeben RC, Goumans MJ, Boon CJF, Koster AJ, Chuva de Sousa Lopes SM, Jost CR, Wijnholds J.: Human iPSC-Derived Retinas Recapitulate the Fetal CRB1 CRB2 Complex Formation and Demonstrate that Photoreceptors and Müller Glia Are Targets of AAV5. Stem Cell Reports 12: 906-919, May 2019.
19f Buck TM, Quinn PMJ, Pellissier LP, Mulder AA, Jongejan A, Koot D, Almushattat H, Arendzen CH, Vos RM, Bradley EJ, Freund C, Mikkers HMM, Boon CJF, van Kampen AH, Baas F, Koster AJ, Neefjes J, Berlin I, Jost CR, Wijnholds J. : CRB1 is required for recycling by RAB11A+ vesicles in human retinal organoids. Stem Cell Reports 18, September 2023.
133 Marques JP, Sousa IS, Patrício D, Simões BF, Chukwunalu O, Zeitz C, Audo I, Collin RWJ, Quinn PMJ, Ambrósio AF, Alves CH: Eyes shut homolog (EYS): Connecting molecule to disease. Progress in Retinal and Eye Research September 2025.
12c Stehle IF, Imventarza JA, Woerz F, Antony S, Hoffmann F, Boldt K, Beyer T, Quinn PMJ, Ueffing M. : Human CRB1-CRB2 interaction support CRB2 as a modifier in CRB1-associated retinal diseases. Life Science Alliance. April 2024.
172 Balasubramanian R, Min X, Quinn PMJ, Giudice QL, Tao C, Polanco K, Makrides N, Peregrin J, Bouaziz M, Mao Y, Wang Q, da Costa BL, Buenaventura D, Wang F, Ma L, Tsang SH, Fabre PJ, Zhang X.: Phase transition specified by a binary code patterns the vertebrate eye cup. Sci Adv 7: eabj9846, Nov 2021.
164 Costa BLD, Quinn PMJ, Wu WH, Nolan ND, Liu S, Wang NK, Demirkol A, Caruso SM, Tsai YT, Kong Y, Cabral T, Belfort R, Tsang SH. : Downregulation of miR-181a/b reprograms the retinal pigment epithelium metabolism in a mouse model of retinitis pigmentosa. Cell and Bioscience. May 2024.
106 Caruso SM, Tsai YT, da Costa BL, Kolesnikova M, Jenny LA, Tsang SH, Quinn PMJ.: Prime Editing Strategy to Install the PRPH2 c.828+1G>A Mutation. Adv Exp Med Biol 1415(1): 97-102, July 2023.
114 Tsai YT, da Costa BL, Caruso SM, Nolan ND, Levi SR, Tsang SH, Quinn PMJ.: Generation of an Avian Myeloblastosis Virus (AMV) Reverse Transcriptase Prime Editor. Adv Exp Med Biol 1415: 109-114, July 2023.
10d Lopes da Costa B, Kolesnikova M, Levi SR, Cabral T, Tsang SH, Maumenee IH, Quinn PMJ.: Clinical and Therapeutic Evaluation of the Ten Most Prevalent CRB1 Mutations. Biomedicines 11: 385, Jan 2023.
2c
4d
22
22
7
10
a
a
2
2
19
18
10
22
10
11
c
5b © The Trustees of the University of Pennsylvania | Site best viewed a in a supported browser. | Site Design: 57 PMACS Web Team. 3 22
10